Drug intelligence / Profile preview

HSB-101

Development stage: Preclinical
Lead developer: Hillstar Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HSB-101 is a preclinical-stage antibody-based immunotherapy being developed by Hillstar Bio for the treatment of axial spondyloarthritis (AxSpA) and other HLA-B27-mediated immune and inflammatory conditions. The drug functions as a selective depleting agent targeting TRBV9+ T cells, a specific subset of pathogenic T cells implicated in driving the inflammatory response in AxSpA. By selectively eliminating these cells while preserving the broader immune system, HSB-101 represents a precision immunology approach designed to offer improved efficacy and safety over traditional broad-spectrum immunosuppressants. Hillstar Bio anticipates that HSB-101 will enter clinical trials in 2026.

Targets

TRBV9 (T-cell receptor beta variable 9)

Beyond the preview

Go deeper on HSB-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSB-101.

Explore the full profile